Latest Factor VII Stories
DUBLIN, May 26, 2015 /PRNewswire/ -- Research and Markets(http://www.researchandmarkets.com/research/htr7g8/2015_strategies)
DUBLIN, May 26, 2015 /PRNewswire/ -- Research and Markets(http://www.researchandmarkets.com/research/9rp2x9/2015_strategies)
DUBLIN, May 27, 2015 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/5t4jwt/2015_strategies) has announced the addition of the "2015 Strategies
MarketReportsOnline.com adds Global Hemophilia Market Report: 2015 Edition research report of 51 pages on the hemophilia industry to the pharmaceuticals intelligence collection of its research store.
DEERFIELD, Ill., April 16, 2015 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) reported today that partner Baxter International Inc.
Landmark Lightings and Community Activities Honor People Affected by the Disorder WESTON, Mass., April 16, 2015 /PRNewswire/ -- In recognition of World Hemophilia Day,
rIX-FP Regulatory Submissions Now Made in EU and U.S.; Underscores CSL Behring's Legacy of Improving the Care for Patients with Bleeding Disorders KING OF PRUSSIA,
PLAINSBORO, N.J., March 26, 2015 /PRNewswire/ -- Novo Nordisk today announced the company will launch Novoeight(®) (Antihemophilic Factor [Recombinant]) in the United States for people living
DEERFIELD, Ill., Feb. 11, 2015 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) reported that partner Baxter International Inc.
CSL Behring Achieves Another Key Milestone in PROLONG-9FP, its Recombinant Factor IX Fusion Protein Development Program; Continues to Advance CSL Behring's Legacy of Improving Patient Well-Being
- The parings of haberdine; also, any kind of fragments.